

## AlzeCure appoints Märta Segerdahl as Chief Medical Officer

**AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced the appointment of Märta Segerdahl, MD, PhD, Associate professor, as Chief Medical Officer (CMO). She will be a member of AlzeCure's executive management team and succeeds An van Es-Johansson, MD, currently CMO and Head of Development, and previously member of the Board, who will continue working for AlzeCure as an advisor.**

Dr. Segerdahl will take on the position as CMO on April 1 and will have the overall medical responsibility for AlzeCure's drug development candidates and will lead the clinical development organization. Dr. Segerdahl has more than 15 years of industry experience from both big pharma and small biotech, with various senior positions in pharmaceutical drug development, focusing on neuroscience. Recent positions include CMO at Asarina Pharma ApS, Chief Medical Specialist at Lundbeck A/S, Senior Medical Director Medical Intelligence at Grünenthal GmbH, and Global Medical Science Director Emerging Cognition at AstraZeneca.

"We are delighted to have Märta joining our team. Her expertise in CNS and solid experience in leading clinical development and building development organizations will strengthen our clinical capacity as we are now maturing the clinical portfolio. Her experience from both big pharma and biotech will also be instrumental in our business development efforts and partnering discussions," said Martin Jönsson, CEO of AlzeCure Pharma.

"I am thrilled to join the AlzeCure team at this important time in the company's development. I hope to be able to apply my many years of clinical experience within neurology and pain as well as my clinical drug development skills to progress AlzeCure's drug candidates to the next level", said Dr. Segerdahl.

"I would also like to express my sincere thanks to Dr van Es-Johansson who has had a decisive role in driving our Development organization and our clinical portfolio through important studies and phases. We look forward working with her as an advisor as we move our exciting project portfolio forward", said Martin Jönsson.

**For more information, please contact**

---

Martin Jönsson, CEO  
Tel: +46 707 86 94 43  
[martin.jonsson@alzecurepharma.com](mailto:martin.jonsson@alzecurepharma.com)

## About AlzeCure Pharma AB (publ)

---

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. Alzstatin comprises two disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a clinical candidate for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase and is continuously working with business development to find suitable out-licensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit [www.alzecurepharma.se](http://www.alzecurepharma.se).

## Image Attachments

---

Märta Segerdahl AlzeCure 1 Sv

## Attachments

---

AlzeCure appoints Märta Segerdahl as Chief Medical Officer